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Oncometabolites: linking altered  
metabolism with cancer
Ming Yang,1 Tomoyoshi Soga,2,3 and Patrick J. Pollard1,4
1Cancer Biology and Metabolism Group, Nuffield Department of Medicine, Henry Wellcome Building for Molecular Physiology, University of Oxford,  
Oxford, United Kingdom. 2Institute for Advanced Biosciences and 3Oxford-Keio Metabolomics Consortium, Keio University, Yamagata, Japan.  
4Oxford-Keio Metabolomics Consortium, Oxford, United Kingdom.
The discovery of cancer-associated mutations in genes encoding key metabolic enzymes has provided a direct link 
between altered metabolism and cancer. Advances in mass spectrometry and nuclear magnetic resonance technolo-
gies have facilitated high-resolution metabolite profiling of cells and tumors and identified the accumulation of 
metabolites associated with specific gene defects. Here we review the potential roles of such “oncometabolites” in 
tumor evolution and as clinical biomarkers for the detection of cancers characterized by metabolic dysregulation.
Introduction
The emerging interest in metabolites whose abnormal accumula-
tion causes both metabolic and nonmetabolic dysregulation and 
potential transformation to malignancy (herein termed “onco-
metabolites”) has been fueled by the identification of cancer-
associated mutations in genes encoding enzymes with significant 
roles in cellular metabolism (1–5). Loss-of-function mutations 
in genes encoding the Krebs cycle enzymes fumarate hydratase 
(FH) and succinate dehydrogenase (SDH) cause the accumula-
tion of fumarate and succinate, respectively (6), whereas gain-of-
function isocitrate dehydrogenase (IDH) mutations increase levels 
of D–2-hydroxyglutarate (D-2HG) (7, 8). These metabolites have 
been implicated in the dysregulation of cellular processes includ-
ing the competitive inhibition of α-ketoglutarate–dependent 
(α-KG–dependent) dioxygenase enzymes (also known as 2-oxo-
glutarate–dependent dioxgenases) and posttranslational modifi-
cation of proteins (1, 4, 9–11). To date, several lines of biochemical 
and genetic evidence support roles for fumarate, succinate, and 
D-2HG in cellular transformation and oncogenesis (3, 12).
Production of oncometabolites in cancer
D-2HG accumulates to millimolar concentrations in tumors with 
monoallelic mutations in IDH1 and IDH2 (8). There are three 
IDH isoforms in humans: IDH1 and IDH2 are NADP+-depen-
dent homodimers localized in the cytoplasm and mitochondria, 
respectively, that catalyze the reversible conversion of isocitrate 
to α-KG, whereas IDH3 is an NAD+-dependent heterotetramer 
and catalyzes the irreversible oxidative decarboxylation of isoci-
trate to α-KG in the Krebs cycle (13). Somatic mutations in IDH1 
and IDH2 occur in multiple human cancers, including low-grade 
glioma and secondary glioblastoma, chondrosarcoma, cholan-
giocarcinoma, and acute myeloid leukemia (AML) (14–19). The 
most common cancer mutations map to single arginine residues 
in the catalytic pockets: IDH1 (R132) and IDH2 (R172 or R140) 
(16, 19, 20). Mutant IDH1/2 forms a dimer with the wild-type copy 
derived from the normal allele and displays a neomorphic activity 
that allows the heterodimeric enzyme to catalyze the reduction of 
α-KG directly to D-2HG in the presence of NADPH (refs. 7, 8, 21, 
22, and Figure 1).
Succinate and fumarate accumulation occur in tumors driven 
by inactivating mutations in SDH and FH, the gene products of 
which catalyze sequential steps in the Krebs cycle. SDH mutations 
are commonly found in hereditary paraganglioma (PGL) and 
pheochromocytoma (PCC), while FH mutations are associated 
with hereditary leiomyomatosis and renal cell cancer (HLRCC) 
(23). Affected individuals inherit a loss-of-function mutation in 
one allele, with their tumors displaying loss of heterozygosity in 
the other allele, usually through somatic deletion or chromosom-
al loss; thus both genes follow the hereditary pattern of typical 
tumor suppressors (24). SDH is a highly conserved heterotetra-
meric protein, with SDHA and SDHB as catalytic subunits and 
SDHC and SDHD as ubiquinone-binding and membrane-anchor-
age subunits. In addition to its role in the Krebs cycle, SDH also 
functions as complex II of the electron transport chain (ETC), cat-
alyzing the oxidation of succinate to fumarate in a reaction that 
generates FADH2, and donates electrons to the ETC. Mutations 
in genes encoding SDH subunits as well as the SDH assembly fac-
tor 2 occur frequently in PGL/PCC, but have also been identified 
in other types of tumors such as gastrointestinal stromal tumors 
(GISTs), renal tumors, thyroid tumors, testicular seminomas, and 
neuroblastomas (25). FH exists as a homotetrameric enzyme that 
catalyzes the stereospecific and reversible hydration of fumarate to 
malate. Though characterized by renal cancer, renal cysts, and skin 
and uterine leiomyomas (26, 27), evidence suggests that FH muta-
tions may also be involved in the pathogenesis of breast, bladder, 
and Leydig cell tumors (28, 29). Both SDH and FH mutations sig-
nificantly reduce their enzymatic activities, leading to accumula-
tion of high levels of succinate and fumarate, respectively (refs. 6, 
30–32, and Figure 2).
Epigenetic alterations
A common oncogenic mechanism linking D-2HG, succinate, and 
fumarate is the inhibition of α-KG–dependent dioxygenases (9), 
particularly of the Jumonji C domain–containing histone lysine 
demethylases (KDMs) and the ten eleven translocation (TET) 
family of 5-methylcytosine (5mC) hydroxylases, which results in 
epigenetic alterations that affect the expression of genes involved 
in cell differentiation and the acquisition of malignant features 
(Figures 1 And 2). Turcan et al. showed that D-2HG accumula-
tion in IDH1-mutant gliomas substantially remodeled the DNA 
methylome and established a distinct CpG island methylator 
phenotype, which can be phenocopied by the stable expression of 
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IDH1 R132H in primary human astrocytes (33). Elevated DNA 
methylation is also observed in AML samples harboring either 
2HG-producing mutations in IDH1/2 or inactivating mutations 
in the α-KG–dependent TET2 enzyme (34, 35), and expression of 
mutant IDH1/2 or treatment with D-2HG is sufficient to inhibit 
TET2 function and impair differentiation in erythroleukemia 
cells (36). Expression of IDH mutants also suppressed histone 
demethylation, which repressed the expression of genes involved 
in lineage-specific differentiation and impaired adipocyte differen-
tiation in culture (37). Taken together, these observations suggest 
that D-2HG acts as an oncogenic driver via epigenetic reprogram-
ming in IDH-associated cancers.
Succinate and fumarate have been shown to inhibit KDM and 
TET enzymes in vitro and in cultured cells, leading to enhanced 
histone methylation marks and decreased global 5-hydroxymeth-
ylcytosine (5hmC) levels (38). Recently, two independent studies 
both demonstrated that succinate could also remodel the cancer 
epigenome. Killian et al. studied the methylation profiles of GIST 
tumors driven by mutations in either SDH or KIT and uncovered 
substantial DNA hypermethylation in the SDH-mutant subgroup 
(39). The authors also examined PGL/PCC tumors and identified 
hypermethylation in those harboring SDH mutations (39). In par-
allel, Letouzé and colleagues classified the methylation status of a 
large PGL/PCC cohort and identified a distinct epigenetic subclus-
ter characterized by a hypermethylator phenotype (40). Strikingly, 
SDH mutations were discovered in 16 of 17 samples from the 
hypermethylated subgroup, in which the expression of 191 genes 
was downregulated concordantly with levels of CpG promoter 
hypermethylation. Two of the most significantly epigenetically 
silenced genes, PNMT and KRT19, are involved in neuroendocrine 
differentiation and epithelial-mesenchymal transition, respective-
ly, which potentially explains the undifferentiated phenotype and 
aggressive nature of SDH-related PGL/PCC. Furthermore, Sdhb-
deficient mouse chromaffin cells exhibit higher 5mC/5hmC ratios 
compared with wild-type cells, which can be reversed by the addi-
tion of exogenous α-KG, supporting the hypothesis that succinate 
inhibits TET-catalyzed DNA modification. Interestingly, the only 
tumor in the hypermethylated PGL/PCC subgroup with wild-type 
SDH harbored germline and somatic FH mutations, strongly sug-
gesting that fumarate may also play a role in epigenetic rewiring 
in HLRCC (40). Finally, both groups analyzed developmentally 
distinct tumors containing SDH and IDH mutations and discov-
ered an overlap in their hypermethylation patterns, potentially 
implicating a shared role for D-2HG, succinate, and fumarate in 
reprogramming of the epigenetic landscape in cancer.
Pseudohypoxia
In SDH- and FH-deficient cells and tumors, the activation of a 
HIF-orchestrated “pseudohypoxic” response has been reported 
(41–44), which could at least in part be attributed to the alloste-
ric inhibition of HIF prolyl hydroxylases (PHDs) by elevated levels 
of succinate or fumarate (Figure 2). Although generally regarded 
as a major player in human cancer by transcriptionally regulat-
ing pathways that facilitate tumor growth and progression, the 
exact role of HIF in tumorigenesis is unclear (45). At least in the 
context of FH deficiency, a causal role for HIF in cancer initiation 
is debatable, as indicated by the observation that combined inac-
tivation of Fh1 and Hif1a in mouse renal tubular cells exacerbated 
the cystic phenotype associated with Fh1 inactivation alone (46). 
Similarly, there have been contradictory observations of HIF lev-
els in IDH-mutant models. Mice bearing the Idh1 R132H mutant 
accumulated Hif-1α and upregulated the expression of Hif target 
genes (47, 48). Ectopic expression of IDH1 R132H also increased 
HIF-1α levels in HEK293T and U-87MG glioblastoma cells 
(49, 50). In contrast, Koivunen et al. showed that, whereas L-2HG 
inhibits PHD activity, D-2HG promotes it by acting as a cofactor 
for these enzymes at pathophysiological concentrations, leading 
to diminished HIF levels, which confers a proliferative advantage 
for human astrocytes in soft agar growth (ref. 51 and Figure 1).
D-2HG is present at low levels in normal cells and can be 
metabolized by the enantiomer-specific D-2HG dehydrogenase 
(D2HGDH) to α-KG (52). Accumulation of either D- or L-2HG 
has been detected in the body fluids of patients with rare meta-
bolic disorders that result from mutations in the corresponding 
Figure 1
D-2HG produced by mutant IDH1/2 affects metabolism and epigenetics 
by modulating activities of α-KG–dependent oxygenases. Wild-type 
IDH1 and IDH2 catalyze the NADP+-dependent reversible conver-
sion of isocitrate to α-KG, whereas cancer-associated gain-of-function 
mutations enable mutant IDH1/2 (mIDH1/2) to catalyze the oxidation of 
α-KG to D-2HG, using NADPH as a cofactor. Because D-2HG is struc-
turally similar to α-KG, its accumulation can modulate the activities of 
α-KG–utilizing dioxygenases. Inhibition of 5mC hydroxylase TET2 and 
the KDMs results in increased CpG island methylation and increased 
histone methylation marks, respectively, thus blocking lineage-specific 
cell differentiation. Inhibition of collagen prolyl and lysyl hydroxylases 
(C-P4Hs and PLODs, respectively) leads to impaired collagen matu-
ration and disrupted basement membrane formation. D-2HG can 
also stimulate the activities of HIF PHDs, leading to enhanced HIF 
degradation and a diminished HIF response, which are associated 
with increased soft agar growth of human astrocytes and growth fac-
tor independence of leukemic cells. Together these processes exert 
pleiotrophic effects on cell signaling and gene expression that probably 
contribute to the malignancy of IDH1/2-mutant cells.
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dehydrogenase D2HGDH or L2HGDH (53, 54). Compared to 
D-2HG, L-2HG is a more potent inhibitor of the α-KG–depen-
dent dioxygenases tested to date (49, 51). Interestingly, there is 
an increased risk for pediatric glioma in systemic L2HGDH defi-
ciency, but not in patients with D2HGDH deficiency (53, 55), 
suggesting that the tumorigenic effect of D-2HG in adult tumors 
may be context specific or dose dependent. Furthermore, gliomas 
harboring IDH1/2 mutations are associated with better progno-
sis (49, 51). Kaelin and colleagues (36) proposed that the seem-
ingly paradoxical observations could potentially be explained by 
the differential effect of D-2HG on HIF PHDs and histone/DNA 
demethylases. The authors showed that IDH1 R132H expression 
promoted growth factor independence and impaired differen-
tiation of erythroleukemia cells, whereas loss of PHD2 activity 
blocked the leukemic transformation induced by IDH1 R132H 
expression or TET2 suppression. At tumor-relevant concentra-
tions, D-2HG exerts an inhibitory effect on TET2 and causes 
epigenetic reprogramming while acting as an agonist for PHDs 
to promote HIF degradation. Indeed, HIF may have a tumor-sup-
pressive effect at least in this setting, supported by the observa-
tions that HIF can inhibit hematopoietic stem cell and leukemic 
cell proliferation (56, 57).
Collagen maturation
Interestingly, recent work employing a small-molecule inhibitor 
against IDH1 R132 suggested that D-2HG might promote can-
cer growth through factors other than its epigenetic effects (58). 
Potential explanations may include modulation of HIF activity 
as discussed above, and dysregulation of other α-KG–dependent 
dioxygenases and corresponding cellular programs. Sasaki et al. 
showed that mice bearing Idh1 R132H mutations exhibit defects 
in collagen protein maturation and disrupted basement membrane 
formation, which could be attributed to D-2HG–mediated inhibi-
tion of collagen prolyl and lysyl hydroxylases and may contribute to 
abnormal tissue morphology and, potentially, glioma progression 
(47, 48). RNA expression array analyses of mutant IDH1 xenograft 
tumors also identified alterations in type IV collagen expression 
(58). Recently, the range of reactions catalyzed by α-KG–depen-
dent dioxygenases has been further extended to ribosome protein 
modifications (59), and it remains to be determined whether trans-
lational processes are also sensitive to D-2HG targeting.
Succination and succinylation
Fumarate is an electrophilic metabolite that can react spontane-
ously with free sulfhydryl groups in cysteine residues by a Michael 
addition reaction to produce S-(2-succino)-cysteine (2SC), a pro-
cess termed succination (60, 61). Succination can impair protein 
function, notably that of Kelch-like ECH-associated protein 1 
(KEAP1), which is a major cellular electrophile sensor and nega-
tive regulator of the transcription factor nuclear factor E2-related 
factor 2 (NRF2) (62). Under normal physiological conditions, 
KEAP1 interacts with NRF2, promoting its ubiquitylation and 
proteasomal-mediated degradation. In the presence of oxidative 
stress or electrophiles, the KEAP1-NRF2 interaction is disrupt-
Figure 2
Candidate oncogenic mechanisms of succi-
nate and fumarate accumulation. SDH and 
FH are Krebs cycle enzymes and tumor sup-
pressors. Loss-of-function mutations in SDH 
and FH result in abnormal accumulation of 
Krebs cycle metabolites succinate (Succ) and 
fumarate (Fum), respectively, both of which 
can inhibit the activities of α-KG–dependent 
oxygenases. Inhibition of HIF PHDs leads to 
activation of HIF-mediated pseudohypoxic 
response, whereas inhibition of KDMs and 
TET family of 5mC hydroxylases causes epi-
genetic alterations. Fumarate is electrophilic 
and can also irreversibly modify cysteine 
residues in proteins by succination. Succi-
nation of KEAP1 in FH deficiency results in 
the constitutive activation of the antioxidant 
defense pathway mediated by NRF2, con-
ferring a reductive milieu that promotes cell 
proliferation. Succination of the Krebs cycle 
enzyme Aco2 impairs aconitase activity in 
Fh1-deficient MEFs. Fumarate accumulation 
may also affect cytosolic pathways by inhibit-
ing the reactions involved in the biosynthesis 
of arginine and purine. AcCoA, acetyl CoA; 
Mal, malate; OAA, oxaloacetate; Succ-CA, 
succinyl CoA.
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ed, resulting in the nuclear translocation of NRF2 and activa-
tion of an assortment of genes involved in antioxidant defense 
(63, 64). Work from ourselves and others demonstrated that in 
FH-deficient cells, KEAP1 is succinated on two critical cysteine 
residues (Cys155 and Cys288), which abrogates its interaction 
with NRF2 and elicits the constitutive expression of NRF2 target 
genes (refs. 46, 65, and Figure 2). Several lines of evidence sug-
gest that activation of the NRF2-mediated antioxidant defense 
pathway may promote tumorigenesis by enhanced ROS detoxifi-
cation as well as conferring a more reduced intracellular environ-
ment that can promote cell survival and proliferation (66, 67). 
This model is also supported by the observations that inactivat-
ing KEAP1 mutations and activating NRF2 mutations are found 
in various human cancers (68) and that NRF2 and its target genes 
are overexpressed in many cancer cell lines and human tumors 
(69–71). The identification of the NRF2 target gene heme oxygen-
ase (decycling) 1 (HMOX1), which encodes a protein involved in 
heme degradation, as synthetically lethal to FH deletion, further 
supports the hypothesis that NRF2 can promote survival of FH-
deficient cells (72), as does the recent discovery of NRF2-activat-
ing somatic mutations in sirtuin 1 (SIRT1), cullin 3 (CUL3), and 
NRF2 in sporadic papillary renal cell carcinomas (translocation 
associated) type 2 (PRCC2) (73).
We recently conducted a proteomic-based screen for novel 2SC 
targets and identified succination in more than 90 proteins in 
Fh1-deficient mouse embryonic fibroblasts (MEFs) and tissues. 
Nearly half of the 2SC targets thus identified are involved in 
metabolic processes, among which we identified the succination 
of the Krebs cycle enzyme aconitase 2 (ACO2) at three cysteine 
residues that are required for iron-sulfur cluster binding (ref. 74 
and Figure 2). Fumarate-mediated succination of ACO2 exerted a 
dose-dependent inhibition on its enzymatic activity in vitro, and 
Fh1-deficient MEFs displayed reduced aconitase activity compared 
with wild-type counterparts. In contrast to other cell lines with 
compromised mitochondrial function, through either mutation 
or hypoxic stress, Fh1-deficient MEFs did not utilize the reductive 
carboxylation pathway for citrate synthesis, possibly due to succi-
nation of ACO2 (74–77). Taken together with previous work dem-
onstrating succination and inhibition of GAPDH activity (78), it is 
plausible that succination is widespread in FH deficiency and that 
fumarate may cause dysregulated metabolism via succination of 
key metabolic proteins, potentially contributing to the oncogen-
esis of HLRCC.
Succination is a distinct process from succinylation, which typi-
cally occurs on lysine residues and is considered to be mediated 
by succinyl coenzyme A, producing a thioester derivative protein 
product (79). Recently, increases in protein succinylation have also 
been shown to occur under conditions where succinate levels are 
elevated and the activity of the desuccinylase SIRT5 is suppressed. 
Succinylated proteins targets identified include malate dehydro-
genase, GAPDH, glutamate carrier 1, L-lactate dehydrogenase A 
chain and transaldolase (80). Protein succinylation levels and func-
tional consequences in SDH-mutant tumors are interesting topics 
for future investigation.
ROS
Dysregulation of mitochondrial function characterized by Krebs 
cycle defects has been associated with overproduction of ROS, 
which may participate in oncogenic signaling and tumor progres-
sion by irreversible modification of DNA and oxidation of proteins 
(81, 82). Mouse fibroblasts transfected with an SDHC mutant dis-
played sustained ROS production and elevated DNA mutation 
frequency (81). A separate study using hamster fibroblasts express-
ing a truncated form of SDHC also showed increased steady-state 
levels of ROS and genomic instability (83). Guzy and colleagues 
further proposed that ROS-induced inactivation of PHDs triggers 
the HIF response in SDH-deficient cells, thus providing an alter-
native model for HIF activation in SDH deficiency (84).
Cells harboring 2HG-producing IDH mutations manifest 
depleted cellular glutamate levels, possibly because the metabo-
lite is shunted to produce α-KG and subsequently converted 
to D-2HG, and elevated NADP+/NADPH ratios as a result of 
impaired generation but increased consumption of NADPH (3). 
Both events could suppress glutathione synthesis and regenera-
tion in IDH mutant cells (85), potentially conferring an oxidative 
intracellular status and affecting biosynthesis. Surprisingly, Idh1 
R132H–expressing mouse brain cells displayed attenuated ROS 
levels despite an increased NADP+/NADPH ratio (47).
Very recently, Sullivan et al. showed that succination of the 
antioxidant glutathione by fumarate in FH-deficient cells 
results in the accumulation of succinated glutathione, which 
acts as an alternative substrate to glutathione reductase, lead-
ing to decreased NADPH levels, enhanced mitochondrial ROS, 
and HIF-1α stabilization (86). Interestingly, the authors showed 
that fumarate-dependent succination, rather than ROS-induced 
oxidation, of KEAP1, is the dominant mechanism for NRF2 acti-
vation in these cells. The NRF2-mediated antioxidant pathways 
in turn serve to mitigate enhanced ROS levels, thus reflecting 
the intricate adaptive mechanisms of FH-deficient cells in com-
bating redox stress.
Fumarate-dependent dysregulation of the urea cycle
The identification of KEAP1 succination suggests that fumarate 
accumulation occurs in subcellular compartments other than 
mitochondria in FH-deficient cells. In addition to its role in the 
Krebs cycle, fumarate also participates in the urea cycle and the 
purine biosynthesis pathway (refs. 87–90 and Figure 2). Recently 
it has been reported that fumarate accumulation can cause rever-
sal of the argininosuccinate lyase–catalyzed reaction in the urea 
cycle, resulting in accumulation of fumarate-derived argininosuc-
cinate and rendering the FH-deficient cells auxotrophic for argi-
nine and sensitive to pharmacological arginine depletion from 
the growth media compared with controls (91, 92). Argininosuc-
cinate accumulation was also detected in kidney and urine sam-
ples of Fh1-deficient mice, raising its potential as a biomarker for 
HLRCC (91, 92). Further, re-expression of cytosolic FH in vivo 
ameliorated both renal cyst development and urea cycle defects 
observed in mice with renal-specific Fh1 deletion, implicating a 
potential role for extra-mitochondrial metabolic pathways in FH-
associated oncogenesis (92).
Biomarkers
IDH mutations correlate with better survival of glioma patients 
(93), hence assessment of IDH mutation status carries signifi-
cant diagnostic and prognostic value. Techniques for routine 
neuropathological detection of IDH mutations include DNA-
based sequencing approaches and immunohistochemistry 
(IHC) staining using mutation-specific antibodies (94–97). 
However, there are at least five reproducible cancer-associated 
mutations that can result in 2HG production, and further, con-
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ventional gene sequencing methods may lead to false positives 
due to genetic polymorphism and sequencing artifacts (98). In 
comparison, screening for elevated 2HG levels is a sensitive and 
specific approach to detect IDH mutations in tumors. Whereas 
patient sera/plasma can be assessed in the case of AML (7, 8, 
21, 99), exciting advances with proton magnetic resonance spec-
troscopy (MRS) have been made in the noninvasive detection of 
2HG in patients with gliomas (100–103). Using MRS sequence 
optimization and spectral fitting techniques, Maher and col-
leagues examined 30 patients with glioma and showed that the 
detection of 2HG correlated 100% with the presence of IDH1 or 
IDH2 mutations (102). Andronesi et al. further demonstrated 
that two-dimensional correlation spectroscopy could effectively 
distinguish 2HG from chemically similar metabolites present 
in the brain (103).
Negative IHC staining for SDHB correlates with the presence 
of SDH mutations, whether in SDHB, SDHC, or SDHD (104). 
This finding is most likely explained by the fact that mutations 
in any of the four subunits of SDH can destabilize the entire 
enzyme complex. PGLs/PCCs associated with an SDHA muta-
tion show negative staining for SDHA as well as SDHB (105). 
Therefore, IHC staining for SDHB is a useful diagnostic tool 
to triage patients for genetic testing of any SDH mutation, and 
subsequent staining for the other subunits may further narrow 
the selection of genes to be tested. In contrast, detection of FH 
protein is often evident in HLRCC tumors due to retention of 
the nonfunctional mutant allele (106). However, staining of cysts 
and tumors for 2SC immunoreactivity reveals a striking correla-
tion between FH inactivation and the presence of 2SC-modified 
protein (2SCP), which is absent in non-HLRCC tumors and nor-
mal tissue controls (106). IHC staining for 2SCP thus provides a 
robust diagnostic biomarker for FH deficiency (107).
Therapeutic targeting
Because D-2HG is a product of neomorphic enzyme activities, 
curtailing the D-2HG supply by specifically inhibiting the mutant 
IDH enzymes provides an elegant approach to target IDH-mutant 
cancers. Indeed, recent reports of small-molecule inhibitors 
against mutant forms of IDH1 and IDH2 demonstrated the fea-
sibility of this method. An inhibitor against IDH2 R140Q was 
shown to reduce both intracellular and extracellular levels of 
D-2HG, suppress cell growth, and increase differentiation of pri-
mary human AML cells (108). Similarly, small-molecule inhibi-
tion of IDH1 R132H suppressed colony formation and increased 
tumor cell differentiation in a xenograft model for IDH1 R132H 
glioma (58). The inhibitors exhibited a cytostatic rather than 
cytotoxic effect, and therefore their therapeutic efficacy over lon-
ger time periods may need further assessment (109). Letouzé et 
al. showed that the DNA methytransferase inhibitor decitabine 
could repress the migration capacities of SDHB-mutant cells (40). 
However, for SDH- and FH-associated cancers, a synthetic lethal-
ity approach is worth exploring because of the pleiotrophic effects 
associated with succinate and fumarate accumulation.
Outlook
The application of next-generation sequencing technologies in the 
field of cancer genomics has substantially increased our under-
standing of cancer biology. Detection of germline and somatic 
mutations in specific tumor types not only expands the current 
repertoire of driver mutations and downstream effectors in tumor-
igenesis, but also sheds light on how oncometabolites may exert 
their oncogenic roles. For example, the identification of mutually 
exclusive mutations in IDH1 and TET2 in AML led to the char-
acterization of TET2 as a major pathological target of D-2HG 
(34, 110). Additionally, the discovery of somatic CUL3, SIRT1, and 
NRF2 mutations in sporadic PRCC2 converges with FH mutation 
in HLRCC, in which NRF2 activation is a consequence of fuma-
rate-mediated succination of KEAP1, indicating the functional 
prominence of the NRF2 pathway in PRCC2 (73). In light of this, 
the identification of somatic mutations in genes encoding the 
chromatin-modifying enzymes histone H3K36 methyltransferase 
(SETD2), histone H3K4 demethylase JARID1C (KDM5C), histone 
H3K27 demethylase UTX (KDM6A), and the SWI/SNF chromatin 
remodelling complex gene PBRM1 in clear cell renal cell carcino-
ma (111–113) highlights the importance of epigenetic modulation 
in human cancer and raises the potential for systematic testing in 
other types of tumors such as those associated with FH mutations.
Technological advances such as those in gas and liquid-
chromatography mass spectrometry (114, 115) and nuclear 
magnetic resonance imaging (102) have greatly improved the 
ability to measure low-molecular-weight metabolites in tumor 
samples with high resolution (116). Combined with metabolic 
flux analyses employing isotope tracers and mathematical mod-
eling, modern-era metabolomic approaches can provide direct 
pathophysiological insights into tumor metabolism and serve as 
an excellent tool for biomarker discovery. Using a data-driven 
approach, Jain and colleagues constructed the metabolic profiles 
of 60 cancer cell lines and discovered glycine consumption as a 
key metabolic event in rapidly proliferating cancer cells (117), 
thus demonstrating the power of metabolomic analyses and the 
relevance to future cancer research and therapeutics.
Acknowledgments
The Cancer Biology and Metabolism Group is funded by Cancer 
Research UK and the European Research Council under the Euro-
pean Community’s Seventh Framework Programme (FP7/2007-
2013)/ERC grant agreement no. 310837 to Dr. Pollard. Professor 
Soga receives funding from a Grant-in-Aid for scientific research 
on Innovative Areas, Japan (no. 22134007), and the Yamagata Pre-
fectural Government and City of Tsuruoka.
Address correspondence to: Patrick J. Pollard, Cancer Biol-
ogy and Metabolism Group, Nuffield Department of Medicine, 
Henry Wellcome Building for Molecular Physiology, Univer-
sity of Oxford, Roosevelt Drive, Oxford, OX3 7BN, United King-
dom. Phone: 44.0.1865287780; Fax: 44.0.1865287787; E-mail: 
patrick.pollard@well.ox.ac.uk.
 1. Yang M, Soga T, Pollard PJ, Adam J. The emerging 
role of fumarate as an oncometabolite. Front Oncol. 
2012;2:85.
 2. Ward PS, Thompson CB. Metabolic reprogram-
ming: a cancer hallmark even warburg did not 
anticipate. Cancer Cell. 2012;21(3):297–308.
 3. Vander Heiden MG, Cantley LC, Thompson CB. 
Understanding the Warburg effect: the metabolic 
requirements of cell proliferation. Science. 2009; 
324(5930):1029–1033.
 4. Thompson CB. Metabolic enzymes as onco-
genes or tumor suppressors. N Engl J Med. 2009; 
360(8):813–815.
 5. Schulze A, Harris AL. How cancer metabolism is 
tuned for proliferation and vulnerable to disrup-
tion. Nature. 2012;491(7424):364–373.
 6. Pollard PJ, et al. Accumulation of Krebs cycle 
intermediates and over-expression of HIF1al-
pha in tumours which result from germline 
FH and SDH mutations. Hum Mol Genet. 2005; 
14(15):2231–2239.
 7. Ward PS, et al. The common feature of leukemia-
associated IDH1 and IDH2 mutations is a neo-
morphic enzyme activity converting alpha-keto-
review series
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 9   September 2013 3657
glutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 
17(3):225–234.
 8. Dang L, et al. Cancer-associated IDH1 mutations pro-
duce 2-hydroxyglutarate. Nature. 2010;465(7300):966.
 9. Kaelin WG. Cancer and altered metabolism: 
potential importance of hypoxia-inducible factor 
and 2-oxoglutarate-dependent dioxygenases. Cold 
Spring Harb Symp Quant Biol. 2011;76:335–345.
 10. DeBerardinis RJ, Thompson CB. Cellular metabo-
lism and disease: what do metabolic outliers teach 
us? Cell. 2012;148(6):1132–1144.
 11. Zhang Z, Tan M, Xie Z, Dai L, Chen Y, Zhao Y. 
Identification of lysine succinylation as a new post-
translational modification. Nat Chem Biol. 2010; 
7(1):58–63.
 12. Mullen AR, DeBerardinis RJ. Genetically-defined 
metabolic reprogramming in cancer. Trends Endo-
crinol Metab. 2012;23(11):552–559.
 13. Frezza C, Pollard PJ, Gottlieb E. Inborn and acquired 
metabolic defects in cancer. J Mol Med (Berl).  
2011;89(3):213–220.
 14. Paschka P, et al. IDH1 and IDH2 mutations are 
frequent genetic alterations in acute myeloid leu-
kemia and confer adverse prognosis in cytogeneti-
cally normal acute myeloid leukemia with NPM1 
mutation without FLT3 internal tandem duplica-
tion. J Clin Oncol. 2010;28(22):3636–3643.
 15. Abbas S, et al. Acquired mutations in the genes 
encoding IDH1 and IDH2 both are recurrent aber-
rations in acute myeloid leukemia: prevalence and 
prognostic value. Blood. 2010;116(12):2122–2126.
 16. Yan H, et al. IDH1 and IDH2 mutations in gliomas. 
N Engl J Med. 2009;360(8):765–773.
 17. Amary MF, et al. IDH1 and IDH2 mutations 
are frequent events in central chondrosarcoma 
and central and periosteal chondromas but not 
in other mesenchymal tumours. J Pathol. 2011; 
224(3):334–343.
 18. Borger DR, et al. Frequent mutation of isocitrate 
dehydrogenase (IDH)1 and IDH2 in cholangio-
carcinoma identified through broad-based tumor 
genotyping. Oncologist. 2012;17(1):72–79.
 19. Mardis ER, et al. Recurring mutations found by 
sequencing an acute myeloid leukemia genome.  
N Engl J Med. 2009;361(11):1058–1066.
 20. Parsons DW, et al. An integrated genomic analysis 
of human glioblastoma multiforme. Science. 2008; 
321(5897):1807–1812.
 21. Gross S, et al. Cancer-associated metabolite 
2-hydroxyglutarate accumulates in acute myelog-
enous leukemia with isocitrate dehydrogenase 1 
and 2 mutations. J Exp Med. 2010;207(2):339–344.
 22. Leonardi R, Subramanian C, Jackowski S, Rock CO. 
Cancer-associated isocitrate dehydrogenase muta-
tions inactivate NADPH-dependent reductive car-
boxylation. J Biol Chem. 2012;287(18):14615–14620.
 23. Bayley JP, Devilee P. Warburg tumours and the 
mechanisms of mitochondrial tumour suppressor 
genes. Barking up the right tree? Curr Opin Genet 
Dev. 2010;20(3):324–329.
 24. Gottlieb E, Tomlinson IP. Mitochondrial tumour 
suppressors: a genetic and biochemical update. Nat 
Rev Cancer. 2005;5(11):857–866.
 25. Bardella C, Pollard PJ, Tomlinson I. SDH muta-
tions in cancer. Biochim Biophys Acta. 2011; 
1807(11):1432–1443.
 26. Tomlinson IP, et al. Germline mutations in FH pre-
dispose to dominantly inherited uterine fibroids, 
skin leiomyomata and papillary renal cell cancer. 
Nat Genet. 2002;30(4):406–410.
 27. Launonen V, et al. Inherited susceptibility to uter-
ine leiomyomas and renal cell cancer. Proc Natl Acad 
Sci U S A. 2001;98(6):3387–3392.
 28. Lehtonen HJ, et al. Increased risk of cancer in 
patients with fumarate hydratase germline muta-
tion. J Med Genet. 2006;43(6):523–526.
 29. Carvajal-Carmona LG, et al. Adult leydig cell 
tumors of the testis caused by germline fumarate 
hydratase mutations. J Clin Endocrinol Metab. 2006; 
91(8):3071–3075.
 30. Gimenez-Roqueplo AP, et al. Functional conse-
quences of a SDHB gene mutation in an apparent-
ly sporadic pheochromocytoma. J Clin Endocrinol 
Metab. 2002;87(10):4771–4774.
 31. Gimenez-Roqueplo AP, et al. The R22X mutation 
of the SDHD gene in hereditary paraganglioma 
abolishes the enzymatic activity of complex II 
in the mitochondrial respiratory chain and acti-
vates the hypoxia pathway. Am J Hum Genet. 2001; 
69(6):1186–1197.
 32. Alam NA, et al. Genetic and functional analyses of 
FH mutations in multiple cutaneous and uterine 
leiomyomatosis, hereditary leiomyomatosis and 
renal cancer, and fumarate hydratase deficiency. 
Hum Mol Genet. 2003;12(11):1241–1252.
 33. Turcan S, et al. IDH1 mutation is sufficient to 
establish the glioma hypermethylator phenotype. 
Nature. 2012;483(7390):479–483.
 34. Figueroa ME, et al. Leukemic IDH1 and IDH2 
mutations result in a hypermethylation phenotype, 
disrupt TET2 function, and impair hematopoietic 
differentiation. Cancer Cell. 2010;18(6):553–567.
 35. Delhommeau F, et al. Mutation in TET2 in myeloid 
cancers. N Engl J Med. 2009;360(22):2289–2301.
 36. Losman JA, et al. (R)-2-hydroxyglutarate is suf-
ficient to promote leukemogenesis and its effects 
are reversible. Science. 2013;339(6127):1621–1625.
 37. Lu C, et al. IDH mutation impairs histone demeth-
ylation and results in a block to cell differentiation. 
Nature. 2012;483(7390):474–478.
 38. Xiao M, et al. Inhibition of alpha-KG-dependent 
histone and DNA demethylases by fumarate and 
succinate that are accumulated in mutations of 
FH and SDH tumor suppressors. Genes Dev. 2012; 
26(12):1326–1338.
 39. Killian JK, et al. Succinate dehydrogenase mutation 
underlies global epigenomic divergence in gastro-
intestinal stromal tumor. Cancer Discov. 2013; 
3(6):648–657.
 40. Letouzé E, et al. SDH mutations establish a hyper-
methylator phenotype in paraganglioma. Cancer 
Cell. 2013;23(6):739–752.
 41. Selak MA, et al. Succinate links TCA cycle dysfunc-
tion to oncogenesis by inhibiting HIF-α prolyl 
hydroxylase. Cancer Cell. 2005;7(1):77–85.
 42. Isaacs JS, et al. HIF overexpression correlates with 
biallelic loss of fumarate hydratase in renal cancer: 
novel role of fumarate in regulation of HIF stability. 
Cancer Cell. 2005;8(2):143–153.
 43. O’Flaherty L, et al. Dysregulation of hypoxia path-
ways in fumarate hydratase-deficient cells is inde-
pendent of defective mitochondrial metabolism. 
Hum Mol Genet. 2010;19(19):3844–3851.
 44. Briere JJ, et al. Mitochondrial succinate is instru-
mental for HIF1alpha nuclear translocation in 
SDHA-mutant fibroblasts under normoxic condi-
tions. Hum Mol Genet. 2005;14(21):3263–3269.
 45. Young RM, Simon MC. Untuning the tumor meta-
bolic machine: HIF-alpha: pro- and antitumori-
genic? Nat Med. 2012;18(7):1024–1025.
 46. Adam J, et al. Renal cyst formation in Fh1-deficient 
mice is independent of the Hif/Phd pathway: roles 
for fumarate in KEAP1 succination and Nrf2 sig-
naling. Cancer Cell. 2011;20(4):524–537.
 47. Sasaki M, et al. D-2-hydroxyglutarate produced by 
mutant IDH1 perturbs collagen maturation and 
basement membrane function. Genes Dev. 2012; 
26(18):2038–2049.
 48. Sasaki M, et al. IDH1(R132H) mutation increases 
murine haematopoietic progenitors and alters epi-
genetics. Nature. 2012;488(7413):656–659.
 49. Xu W, et al. Oncometabolite 2-hydroxyglutarate is a 
competitive inhibitor of alpha-ketoglutarate-depen-
dent dioxygenases. Cancer Cell. 2011;19(1):17–30.
 50. Zhao S, et al. Glioma-derived mutations in IDH1 
dominantly inhibit IDH1 catalytic activity and 
induce HIF-1alpha. Science. 2009;324(5924):261–265.
 51. Koivunen P, et al. Transformation by the (R)-enan-
tiomer of 2-hydroxyglutarate linked to EGLN acti-
vation. Nature. 2012;483(7390):484–488.
 52. Wanders RJ, Mooyer P. D-2-hydroxyglutaric acid-
aemia: identification of a new enzyme, D-2-hydrox-
yglutarate dehydrogenase, localized in mitochon-
dria. J Inherit Metab Dis. 1995;18(2):194–196.
 53. Struys EA. D-2-Hydroxyglutaric aciduria: unrav-
elling the biochemical pathway and the genetic 
defect. J Inherit Metab Dis. 2006;29(1):21–29.
 54. Kranendijk M, Struys EA, Salomons GS, Van der 
Knaap MS, Jakobs C. Progress in understanding 
2-hydroxyglutaric acidurias. J Inherit Metab Dis. 2012; 
35(4):571–587.
 55. Kranendijk M, et al. IDH2 mutations in patients 
with D-2-hydroxyglutaric aciduria. Science. 2010; 
330(6002):336.
 56. Pollard PJ, Kranc KR. Hypoxia signaling in hema-
topoietic stem cells: a double-edged sword. Cell 
Stem Cell. 2010;7(3):276–278.
 57. Suda T, Takubo K, Semenza GL. Metabolic regu-
lation of hematopoietic stem cells in the hypoxic 
niche. Cell Stem Cell. 2011;9(4):298–310.
 58. Rohle D, et al. An inhibitor of mutant IDH1 delays 
growth and promotes differentiation of glioma 
cells. Science. 2013;340(6132):626–630.
 59. Ge W, et al. Oxygenase-catalyzed ribosome hydrox-
ylation occurs in prokaryotes and humans. Nat 
Chem Biol. 2012;8(12):960–962.
 60. Nagai R, et al. Succination of protein thiols during 
adipocyte maturation: a biomarker of mitochon-
drial stress. J Biol Chem. 2007;282(47):34219–34228.
 61. Alderson NL, et al. S-(2-Succinyl)cysteine: a novel 
chemical modification of tissue proteins by a Krebs 
cycle intermediate. Arch Biochem Biophys. 2006; 
450(1):1–8.
 62. Sun Z, Zhang S, Chan JY, Zhang DD. Keap1 con-
trols postinduction repression of the Nrf2-mediat-
ed antioxidant response by escorting nuclear export 
of Nrf2. Mol Cell Biol. 2007;27(18):6334–6349.
 63. Itoh K, et al. An Nrf2/small Maf heterodimer medi-
ates the induction of phase II detoxifying enzyme 
genes through antioxidant response elements.  
Biochem Biophys Res Commun. 1997;236(2):313–322.
 64. Itoh K, et al. Keap1 represses nuclear activation of 
antioxidant responsive elements by Nrf2 through 
binding to the amino-terminal Neh2 domain. 
Genes Dev. 1999;13(1):76–86.
 65. Ooi A, et al. An antioxidant response phenotype 
shared between hereditary and sporadic type 2 
papillary renal cell carcinoma. Cancer Cell. 2011; 
20(4):511–523.
 66. DeNicola GM, et al. Oncogene-induced Nrf2 tran-
scription promotes ROS detoxification and tumor-
igenesis. Nature. 2011;475(7354):106–109.
 67. Mitsuishi Y, et al. Nrf2 redirects glucose and glu-
tamine into anabolic pathways in metabolic repro-
gramming. Cancer Cell. 2012;22(1):66–79.
 68. Hayes JD, McMahon M. NRF2 and KEAP1 muta-
tions: permanent activation of an adaptive response 
in cancer. Trends Biochem Sci. 2009;34(4):176–188.
 69. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. 
Dual roles of Nrf2 in cancer. Pharmacol Res. 2008; 
58(5–6):262–270.
 70. Inami Y, et al. Persistent activation of Nrf2 through 
p62 in hepatocellular carcinoma cells. J Cell Biol. 
2011;193(2):275–284.
 71. Network TCGAR. Comprehensive genomic char-
acterization of squamous cell lung cancers. Nature. 
2012;489(7417):519–525.
 72. Frezza C, et al. Haem oxygenase is synthetically 
lethal with the tumour suppressor fumarate hydra-
tase. Nature. 2011;477:225–228.
 73. Ooi A, et al. CUL3 and NRF2 mutations con-
fer an NRF2 activation phenotype in a sporadic 
form of papillary renal cell carcinoma. Cancer Res. 
2013;73(7):2044–2051.
review series
3658 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 9   September 2013
 74. Ternette N, et al. Inhibition of mitochondrial 
aconitase by succination in fumarate hydratase 
deficiency. Cell Rep. 2013;3(3):689–700.
 75. Metallo CM, et al. Reductive glutamine metabo-
lism by IDH1 mediates lipogenesis under hypoxia. 
Nature. 2012;481(7381):380–384.
 76. Mullen AR, et al. Reductive carboxylation supports 
growth in tumour cells with defective mitochon-
dria. Nature. 2012;481(7381):385–388.
 77. Wise DR, et al. Hypoxia promotes isocitrate 
dehydrogenase-dependent carboxylation of 
α-ketoglutarate to citrate to support cell growth 
and viability. Proc Natl Acad Sci U S A. 2011; 
108(49):19611–19616.
 78. Blatnik M, Frizzell N, Thorpe SR, Baynes JW. 
Inactivation of glyceraldehyde-3-phosphate dehy-
drogenase by fumarate in diabetes: formation of 
S-(2-succinyl)cysteine, a novel chemical modifica-
tion of protein and possible biomarker of mito-
chondrial stress. Diabetes. 2008;57(1):41–49.
 79. Frizzell N, Lima M, Baynes JW. Succination of pro-
teins in diabetes. Free Radic Res. 2011;45(1):101–109.
 80. Tannahill GM, et al. Succinate is an inflamma-
tory signal that induces IL-1beta through HIF-1α. 
Nature. 2013;496(7444):238–242.
 81. Ishii T, Yasuda K, Akatsuka A, Hino O, Hart-
man PS, Ishii N. A mutation in the SDHC gene 
of complex II increases oxidative stress, resulting 
in apoptosis and tumorigenesis. Cancer Res. 2005; 
65(1):203–209.
 82. Ishii N, et al. A mutation in succinate dehydroge-
nase cytochrome b causes oxidative stress and age-
ing in nematodes. Nature. 1998;394(6694):694–697.
 83. Slane BG, et al. Mutation of succinate dehydroge-
nase subunit C results in increased O2.-, oxidative 
stress, and genomic instability. Cancer Res. 2006; 
66(15):7615–7620.
 84. Guzy RD, Sharma B, Bell E, Chandel NS, 
Schumacker PT. Loss of the SdhB, but Not the 
SdhA, subunit of complex II triggers reactive oxy-
gen species-dependent hypoxia-inducible factor 
activation and tumorigenesis. Mol Cell Biol. 2008; 
28(2):718–731.
 85. Reitman ZJ, et al. Profiling the effects of isocitrate 
dehydrogenase 1 and 2 mutations on the cel-
lular metabolome. Proc Natl Acad Sci U S A. 2011; 
108(8):3270–3275.
 86. Sullivan LB, et al. The Proto-oncometabolite fuma-
rate binds glutathione to amplify ROS-dependent 
signaling. Mol Cell. 2013;51(2):236–248
 87. Shambaugh GE. Urea biosynthesis I. The urea cycle 
and relationships to the citric acid cycle. Am J Clin 
Nutr. 1977;30(12):2083–2087.
 88. Brosnan ME, Brosnan JT. Renal arginine metabo-
lism. J Nutr. 2004;134(10 suppl):2791S–2795S.
 89. Stepinski J, Bizon D, Piec G, Angielski S. The 
purine nucleotide cycle activity in renal cortex and 
medulla. Am J Kidney Dis. 1989;14(4):307–309.
 90. Salway JG. Metabolism At A Glance. Oxford, United 
Kingdom: Blackwell Publishing; 1999.
 91. Zheng L, et al. Reversed argininosuccinate lyase 
activity in fumarate hydratase-deficient cancer 
cells. Cancer Metab. 2013;1:12.
 92. Adam J, et al. A role for cytosolic fumarate hydra-
tase in urea cycle metabolism and renal neoplasia. 
Cell Rep. 2013;3(5):1440–1448.
 93. Hartmann C, et al. Type and frequency of IDH1 
and IDH2 mutations are related to astrocytic and 
oligodendroglial differentiation and age: a study 
of 1,010 diffuse gliomas. Acta Neuropathol. 2009; 
118(4):469–474.
 94. De Witte O, Lefranc F, Levivier M, Salmon I, Brot-
chi J, Goldman S. FDG-PET as a prognostic fac-
tor in high-grade astrocytoma. J Neurooncol. 2000; 
49(2):157–163.
 95. Preusser M, Capper D, Hartmann C. IDH testing 
in diagnostic neuropathology: review and practical 
guideline article invited by the Euro-CNS research 
committee. Clin Neuropathol. 2011;30(5):217–230.
 96. Preusser M, Wohrer A, Stary S, Hoftberger R, 
Streubel B, Hainfellner JA. Value and limitations 
of immunohistochemistry and gene sequencing for 
detection of the IDH1-R132H mutation in diffuse 
glioma biopsy specimens. J Neuropathol Exp Neurol. 
2011;70(8):715–723.
 97. Metellus P, et al. IDH mutation status impact 
on in vivo hypoxia biomarkers expression: new 
insights from a clinical, nuclear imaging and 
immunohistochemical study in 33 glioma patients. 
J Neurooncol. 2011;105(3):591–600.
 98. Ward PS, et al. Identification of additional IDH 
mutations associated with oncometabolite R(-)-
2-hydroxyglutarate production. Oncogene. 2012; 
31(19):2491–2498.
 99. Pollyea DA, et al. 2-Hydroxyglutarate in IDH 
mutant acute myeloid leukemia: predicting patient 
responses, minimal residual disease and correla-
tions with methylcytosine and hydroxymethylcy-
tosine levels. Leuk Lymphoma. 2013;54(2):408–410.
 100. Pope WB, et al. Non-invasive detection of 2-hydrox-
yglutarate and other metabolites in IDH1 mutant 
glioma patients using magnetic resonance spec-
troscopy. J Neurooncol. 2012;107(1):197–205.
 101. Elkhaled A, et al. Magnetic resonance of 2-hydrox-
yglutarate in IDH1-mutated low-grade gliomas. 
Sci Transl Med. 2012;4(116):116ra115.
 102. Choi C, et al. 2-hydroxyglutarate detection by 
magnetic resonance spectroscopy in IDH-mutated 
patients with gliomas. Nat Med. 2012;18(4):624–629.
 103. Andronesi OC, et al. Detection of 2-hydroxy-
glutarate in IDH-mutated glioma patients by in 
vivo spectral-editing and 2D correlation mag-
netic resonance spectroscopy. Sci Transl Med. 2012; 
4(116):116ra114.
 104. van Nederveen FH, et al. An immunohistochemical 
procedure to detect patients with paraganglioma 
and phaeochromocytoma with germline SDHB, 
SDHC, or SDHD gene mutations: a retrospec-
tive and prospective analysis. Lancet Oncol. 2009; 
10(8):764–771.
 105. Korpershoek E, et al. SDHA immunohistochemistry 
detects germline SDHA gene mutations in 
apparently sporadic paragangliomas and pheo-
chromocytomas. J Clin Endocrinol Metab. 2011; 
96(9):E1472–E1476.
 106. Bardella C, et al. Aberrant succination of proteins 
in fumarate hydratase-deficient mice and HLRCC 
patients is a robust biomarker of mutation status. 
J Pathol. 2011;225(1):4–11.
 107. Maxwell PH. Seeing the smoking gun: a sensitive 
and specific method to visualize loss of the tumour 
suppressor, fumarate hydratase, in human tissues. 
 J Pathol. 2011;225(1):1–3.
 108. Wang F, et al. Targeted inhibition of mutant IDH2 
in leukemia cells induces cellular differentiation. 
Science. 2013;340(6132):622–626.
 109. Kim J, DeBerardinis RJ. Cancer. Silencing a meta-
bolic oncogene. Science. 2013;340(6132):558–559.
 110. Gaidzik VI, et al. TET2 mutations in acute myeloid 
leukemia (AML): results from a comprehensive 
genetic and clinical analysis of the AML study 
group. J Clin Oncol. 2012;30(12):1350–1357.
 111. Varela I, et al. Exome sequencing identifies frequent 
mutation of the SWI/SNF complex gene PBRM1 in 
renal carcinoma. Nature. 2011;469(7331):539–542.
 112. Dalgliesh GL, et al. Systematic sequencing of renal 
carcinoma reveals inactivation of histone modify-
ing genes. Nature. 2010;463(7279):360–363.
 113. van Haaften G, et al. Somatic mutations of the 
histone H3K27 demethylase gene UTX in human 
cancer. Nat Genet. 2009;41(5):521–523.
 114. Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M, 
Nishioka T. Quantitative metabolome analysis 
using capillary electrophoresis mass spectrometry. 
J Proteome Res. 2003;2(5):488–494.
 115. Soga T, et al. Differential metabolomics reveals 
ophthalmic acid as an oxidative stress biomarker 
indicating hepatic glutathione consumption. J Biol 
Chem. 2006;281(24):16768–16776.
 116. Tomita M, Kami K. Cancer. Systems biology, metab-
olomics, and cancer metabolism. Science. 2012; 
336(6084):990–991.
 117. Jain M, et al. Metabolite profiling identifies a key 
role for glycine in rapid cancer cell proliferation. 
Science. 2012;336(6084):1040–1044.
